Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Tag: amyloid beta

May 13, 2024 CD as API / Pharma applications

The Single Toxin Origin of Alzheimer’s Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention

New data suggest that the aggregation of misfolded native proteins initiates and drives the pathogenic cascade that leads to Alzheimer’s

Continue reading

December 18, 2023 CD as API / Pharma applications / Uncategorized

HPBCD was tested as a possible therapeutic agent in Amyotrophic Lateral Sclerosis (ALS) model

Amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND), is a rare and terminal neurodegenerative disease that results

Continue reading

November 10, 2022 CD as API / Food / Pharma applications

Beer to prevent Alzheimer Disease

Beer is one of the oldest and most popular beverages in the world. Its bitter taste comes from the hops

Continue reading

March 12, 2022 Life sciences

KLVFF oligopeptide-decorated amphiphilic cyclodextrin nanomagnets for selective amyloid beta recognition and fishing for selective amyloid beta recognition and fishing

Recognition and capture of amyloid beta is a challenging task for the early diagnosis of neurodegenerative disorders, such as Alzheimer’s

Continue reading

September 3, 2020 Drug delivery / Pharma applications

Delivering Crocetin across the Blood-Brain Barrier by Using γ-Cyclodextrin to Treat Alzheimer’s Disease

Scientific report has published a paper on γ-cyclodextrin-enabled crocetin formulation which can deliver crocetin into the brain. [1] Crocetin (CRT)

Continue reading

January 15, 2019 Drug delivery

Antibiotics degradation products against Alzheimer’s disease

A recent paper in Cell Reports published an interesting finding: polymeric degradation products (compound X and Z, respectively) of antibiotics

Continue reading

November 6, 2018 CD as API / Pharma applications

HPBCD treatment of Alzheimer’s disease

CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with

Continue reading

Recent Posts

  • Events of American Cyclodextrin Consortium
  • Ultrafast-dissolving ocular microneedle patch with voriconazole-cyclodextrin complex
  • Nano-Enabled Toxicity of Pharmaceutical Excipients
  • Cyclodextrins Across the Eye-Care Spectrum
  • Biphasic dissolving microneedles with cyclodextrin inclusion complexes for enhanced delivery of poorly soluble drugs

Tags

alpha-CD atherosclerosis Cancer therapy Captisol Cholesterol Clinical trial conference Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems electrospinning FDA Food gamma-CD Gilead HPBCD hydrogel methyl BCD Nanoparticles Niemann Pick Disease RAMEB remdesivir review SBECD Special issue Sugammadex Synthesis

Follow Us

  • LinkedIn
  • X
  • Facebook

Categories

  • Agriculture (27)
  • Analysis (66)
  • CD as API (347)
  • CD derivatives (410)
  • Cosmetics and toilettry (51)
  • Diagnosis (12)
  • Drug delivery (790)
  • E-ducation (63)
  • Environmental (134)
  • Events (234)
  • Food (221)
  • Gene delivery (20)
  • Household products (4)
  • Household products (1)
  • In Hungarian (4)
  • Life sciences (42)
  • Non-pharma applications (399)
  • Other industrial use (106)
  • Pharma applications (1,182)
  • Supramolecular systems (40)
  • Uncategorized (146)

Top Posts

  • Events of American Cyclodextrin Consortium
  • Cyclarity Unveils First-Ever Clinical Data Demonstrating Excretion of Oxidized Cholesterol, at American Heart Association Vascular Discovery Scientific Sessions
  • Using cyclodextrin is not rocket science...except for NASA researchers.
  • FDA Grants Approval to HPBCD-Enhanced Biologic: A 'Super-Originator' Formulation
  • HPαCD Therapy: A Breakthrough for Krabbe Disease Treatment
  • Cyclodextrin dimers to treat atherosclerotic plaques by targeting various forms of cholesterol
  • Ex Vivo Drug Screening Assay with Artificial Membranes: Characterizing Cholesterol Desorbing Competencies of Beta-Cyclodextrins
  • HPaCD against Alzheimer Disease
  • Launch of KLEPTOSE® Crysmeb Methyl-Beta-Cyclodextrin for Oral and Parenteral Formulations
  • Global Summit on Pharmaceutical and Medicinal Chemistry (PMC2022)

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 4,472 other subscribers

Loading Comments...